# EDGAR Filing Document

**Accession Number:** 0000721371
**File Stem:** 0000721371-26-000020
**Filing Date:** 2026-6
**Character Count:** 29399
**Document Hash:** 7b6f8f38bf9522f19dac7407532d51d0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000721371-26-000020.hdr.sgml**: 20260601

**ACCESSION NUMBER**: 0000721371-26-000020

**CONFORMED SUBMISSION TYPE**: SD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260601

**DATE AS OF CHANGE**: 20260601

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CARDINAL HEALTH INC
- **CENTRAL INDEX KEY:** 0000721371
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 310958666
- **STATE OF INCORPORATION:** OH
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** SD
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11373
- **FILM NUMBER:** 261050664

**BUSINESS ADDRESS:**
- **STREET 1:** 7000 CARDINAL PLACE
- **CITY:** DUBLIN
- **STATE:** OH
- **ZIP:** 43017
- **BUSINESS PHONE:** 6147573033

**MAIL ADDRESS:**
- **STREET 1:** 7000 CARDINAL PLACE
- **CITY:** DUBLIN
- **STATE:** OH
- **ZIP:** 43017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CARDINAL DISTRIBUTION INC
- **DATE OF NAME CHANGE:** 19920703

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM SD**

**Specialized Disclosure Report**

**Cardinal Health, Inc.**

**(Exact name of the registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Ohio** | **1-11373** | **31-0958666** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(State or other<br>jurisdiction of incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

---

**7000 Cardinal Place, Dublin, Ohio 43017**

**(Address of principal executive offices) (Zip code)** 

**Jessica L. Mayer**

**Chief Legal and Compliance Officer (614) 757-5000**

**(Name and telephone number, including area code, of the person to** 

**contact in connection with this report)** 

Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:

☑&nbsp;&nbsp;&nbsp;&nbsp;Rule 13p-1 under the Securities Exchange Act (17 CFR 204.13p-1) for the reporting period from January 1, 2025 to December 31, 2025.

□&nbsp;&nbsp;&nbsp;&nbsp;Rule 13q-1 under the Securities Exchange Act (17CFR 204.13q-1) for the fiscal year ended <u>&nbsp;&nbsp;&nbsp;&nbsp;</u>.

------

**Section 1 - Conflict Minerals Disclosure**

**Item 1.01. Conflict Minerals Disclosure and Report Conflict Minerals Disclosure**

A copy of Cardinal Health, Inc.'s Conflict Minerals Report for the reporting period from January 1, 2025 to December 31, 2025 is filed as Exhibit 1.01 hereto and is publicly available on the company's website at https://www.cardinalhealth.com/en/about-us/environmental-social-governance/policies-and-principles.html. Information contained on our website is not incorporated by reference into this Form SD or the accompanying Conflict Minerals Report.

**Item 1.02. Exhibit**

A copy of the Conflict Minerals Report is attached hereto as Exhibit 1.01 and incorporated herein by this reference.

**Section 2 - Resource Extraction Issuer Disclosure**

**Item 2.01. Resource Extraction Issuer Disclosure and Report**

Not applicable.

**Section 3 - Exhibits Item 3.01. Exhibits**

**<u>Exhibit</u> <u>No.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Description</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.01&nbsp;&nbsp;&nbsp;&nbsp;<u>[Conflict](cardinalhealth-cmrry2025.htm)</u> <u>[Minerals](cardinalhealth-cmrry2025.htm)</u> <u>[Report](cardinalhealth-cmrry2025.htm)</u> <u>[for](cardinalhealth-cmrry2025.htm)</u> <u>[the](cardinalhealth-cmrry2025.htm)</u> <u>[reporting](cardinalhealth-cmrry2025.htm)</u> <u>[period](cardinalhealth-cmrry2025.htm)</u> <u>[from](cardinalhealth-cmrry2025.htm)</u> <u>[January](cardinalhealth-cmrry2025.htm)</u> <u>[1,](cardinalhealth-cmrry2025.htm)</u> <u>[2025](cardinalhealth-cmrry2025.htm)</u> <u>[to](cardinalhealth-cmrry2025.htm)</u> <u>[December](cardinalhealth-cmrry2025.htm)</u> <u>[31,](cardinalhealth-cmrry2025.htm)</u> <u>[202](cardinalhealth-cmrry2025.htm)</u><u>[5](cardinalhealth-cmrry2025.htm)</u>

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

---

| | | | |
|:---|:---|:---|:---|
| | | **Cardinal Health, Inc.** | **Cardinal Health, Inc.** |
| | | (Registrant) | (Registrant) |
| Date: | June 1, 2026 | By: | /s/ JESSICA L. MAYER |
|  |  |  | Jessica L. Mayer |
|  |  |  | Chief Legal and Compliance Officer |

---

## Exhibit 1.01

Exhibit 1.01

**Cardinal Health, Inc. Conflict Minerals Report**

**For the 2025 Reporting Period**

**Introduction**

As used in this report, "Cardinal Health," "we," "our," "us," and similar pronouns refer to Cardinal Health, Inc. and its consolidated subsidiaries at the end of 2025, unless the context indicates otherwise. "Conflict minerals" (or "3TG") are defined as columbite-tantalite (coltan), cassiterite, gold, and wolframite and the derivatives tantalum, tin, and tungsten.

Cardinal Health is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists, and manufacturers for integrated care coordination.

Our organizational and financial reporting structure consists of two reportable segments: Pharmaceutical and Specialty Solutions segment and Global Medical Products and Distribution ("GMPD") segment and three operating segments that are not significant enough to require separate reportable segment disclosures: Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics. Nuclear and Precision Health Solutions, At-Home Solutions and OptiFreight® Logistics are reported together as "Other."

Our Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over- the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products, provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers, and repackages generic pharmaceuticals and over-the-counter healthcare products and includes our managed services organization platforms for specialty physician offices.

Our GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, which are sold in the United States, Canada, Europe, Asia, and other markets. In addition to distributing Cardinal Health brand products, this segment also distributes a broad range of medical, surgical, and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers in the United States and Canada.

Our Pharmaceutical and Specialty Solutions segment, which generated approximately 92% of our consolidated revenue for our fiscal year ended June 30, 2025, did not have any in-scope products under the 3TG Rule (as defined below). Accordingly, most of our business activities did not come within the scope of the 3TG Rule.

Pursuant to Rule 13p-1 under the Securities Exchange Act of 1934 and Form SD (together, the "3TG Rule"), this Conflict Minerals Report describes, for the period from January 1, 2025 to December 31, 2025 (the "2025 Reporting Period"), our reasonable country of origin inquiry ("RCOI") and the measures we have taken to exercise due diligence on the source and chain of custody of the 3TG contained in, and necessary to the functionality or production of, the products that we manufactured or contracted to manufacture during the 2025 Reporting Period.

**In-Scope Products and Our Supply Chain**

We assessed all product lines manufactured or contracted to be manufactured by us in the 2025 Reporting Period to determine whether they potentially contained necessary 3TG. Through the assessment process, our product teams determined that certain product lines manufactured or contracted to be manufactured by our GMPD segment (collectively, the "Products"), including RFID technology, compression therapy, enteral feeding, electrode, and thermometry product lines, contained necessary 3TG for the 2025 Reporting Period.

Our supply chains are complex and fragmented. As a "downstream" company, we are many tiers removed in the minerals supply chain from smelters and refiners (collectively, "SORs") that process the 3TG found in the Products, with many intervening third parties between the original sources of 3TG and us.

**Reasonable Country of Origin Inquiry**

As required by the 3TG Rule, we conducted a good faith RCOI regarding the 3TG in materials, components, and finished goods supplied to us that relate to the Products. The RCOI was designed to determine whether any of the 3TG originated in the Democratic Republic of the Congo or its adjoining countries (collectively, the "Covered Countries") and was not from recycled or scrap sources. Selected elements of our RCOI process are described below.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• With the assistance of a third-party vendor with expertise in supply chain traceability (the "Vendor") and a Software as a Service ("SaaS") platform for tracking, we engaged 19 potentially in-scope suppliers to collect information regarding the presence and source of 3TG in the Products. These suppliers were asked to create a profile on the Vendor's SaaS platform and complete an online questionnaire based on the Responsible Minerals Initiative's (the "RMI's") Conflict Minerals Reporting Template ("CMRT") version 6.5. The CMRT is an internationally recognized standardized reporting form developed by the RMI that requests, among other things, information regarding the SORs that processed the 3TG in the supplier's products, the country of origin of that 3TG, and the supplier's compliance program. The RMI is a cross-industry organization that provides resources, tools, and information to help companies source minerals conflict-free, including a list of conformant SORs, and manages the Responsible Minerals Assurance Process (the "RMAP"). The RMAP assessment employs a risk-based approach to validate SORs' company-level management processes for responsible minerals procurement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The SaaS platform generated automated reminders for unresponsive suppliers. When suppliers were unresponsive to the reminders generated from the SaaS platform, the Vendor or our employees followed up with personalized emails and offered assistance and further information about the requirements of the 3TG Rule and our compliance expectations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Vendor identified and followed up on incomplete or contradictory answers submitted by suppliers and encouraged them to re- submit with corrected information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Where suppliers identified SORs in their responses, the Vendor verified whether the listed entities matched known SORs and SORs that conform to the RMI's RMAP assessment protocols. The RMAP uses an independent third-party assessment of SOR management systems and sourcing practices to validate conformance with RMAP standards. Our suppliers identified a total of 337 known SORs, of which206 were listed by the RMI as being "conformant" as of April 21st, 2026 and 10 were listed as being "active" in the conformance assessment process. The majority of the responses we received were prepared at a company level, meaning that they covered all the supplier's products and not just those that the supplier sold to us. Based on this reporting, we were not able to determine with certainty whether the identified SORs processed the 3TG contained in the Products. In addition, given the complexity of the supply chain, suppliers may not have identified all the SORs in their supplychains.

Based on our RCOI, we have reason to believe that at least some of the 3TG contained in the Products may have originated in the Covered Countries and may not be from recycled or scrap sources. Accordingly, we exercised due diligence on the source and chain of custody of the 3TG.

**Due Diligence**

The due diligence measures described below were designed to conform, in all material respects, with the applicable portions of the Organisation for Economic Co-operation and Development Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict- Affected and High-Risk Areas, including the Supplements for tin, tantalum and tungsten and gold (Third Edition) (the "OECD Guidance").

The OECD Guidance identifies five steps for due diligence that should be implemented and provides specific guidance with respect to each step. We developed our due diligence measures utilizing the OECD-aligned RMI model to address each of these five steps and to help ensure that the 3TG in the Products is responsibly sourced. These measures considered the OECD Guidance's recommendations for companies in the downstream segments of the supply chain, which typically are several tiers removed from, and have no direct relationships with, SORs. The following discussion addresses each of the five steps in turn.

1.<u>Establish Company Management</u> <u>Systems</u>

We have implemented a 3TG compliance program (the "Program") with the following attributes:

*Policy Statement*

We have adopted a Conflict Minerals Policy (the "Policy") that sets forth the expectation that our suppliers source materials from suppliers that also source responsibly, including from conflict-free mines in the Covered Countries. The Policy is available on our website at https:// www.cardinalhealth.com/en/about-us/environmental-social-governance/policies-and-principles.html. Information contained on our website is not incorporated by reference into this report or the Form SD.

The Policy states that we expect suppliers to be aware of the requirements of the 3TG Rule and other 3TG legislation and to respond in a timely manner to our requests for information. As stated in the Policy, we do not embargo sourcing from the Covered Countries and encourage our suppliers to continue to source responsibly from those countries.

------

*Program Management*

The Corporate ESG team oversees the Program. This team, which manages supplier due diligence with respect to environmental and social issues, reports up to our senior leadership.

*Control Systems and Supply Chain Transparency*

As discussed above, the Vendor facilitates supplier engagement and assists us in collecting, analyzing, verifying, and storing supplier- provided data and performing due diligence for the Program. With the assistance of the Vendor, we contacted and solicited information from suppliers concerning the usage and source of 3TG, using the RMI-aligned approach and questions based on the RMI's CMRT.

Our Vendor Code of Conduct requires suppliers to comply with the Policy, including working with their suppliers to identify the source and chain of custody of any 3TG contained in their products. Under the Vendor Code of Conduct, suppliers must agree to cooperate with us in connection with any inquiries or due diligence that we choose to perform with respect to such 3TG. The Vendor Code of Conduct is available on our website at https://www.cardinalhealth.com/en/about-us/environmental-social-governance/policies-and-principles.html.

The Vendor and SaaS provider maintain records of product and supply chain information collected through the due diligence activities carried out under the Program. Documentation is retained for at least five years in an electronic database.

*Supplier Engagement*

In support of our Policy, we have incorporated 3TG compliance provisions into the standard terms of our GMPD segment's supplier agreement template. As discussed above, we also address 3TG compliance in the Policy and the Vendor Code of Conduct. Both documents are distributed to suppliers and publicly available on our website.

*Grievance Mechanism*

We have a dedicated email address for reporting questions or concerns relating to our Policy or Program to a Cardinal Health representative. The email address is conflict_minerals@cardinalhealth.com. In addition, we have a business conduct line that provides a mechanism for anyone to anonymously report conduct they know or suspect is in violation of Cardinal Health guidelines or policies, including any concerns related to the 3TG supply chain. The contact information for this mechanism is found in our Standards of Business Conduct, which is available on our website at https://www.cardinalhealth.com/en/about-us/who-we-are/ethics-and-compliance.html.

2.<u>Risk Identification and Assessment in the Supply</u> <u>Chain</u>

Risks are identified by the Vendor's software based on "red flag" criteria established for supplier responses, including the submission of responses to questions based on the RMI's CMRT where there were incomplete or contradictory answers. These risks are addressed in the first instance by the Vendor's staff, who contact the supplier, gather pertinent data, and perform an assessment of the supplier's 3TG sourcing risk. The results of the Vendor's outreach campaign and review of supplier responses, including the Vendor's risk assessment, are communicated to our senior leadership.

Possible sourcing risks are identified by the Vendor by assessing the due diligence practices of SORs listed in our suppliers' responses. The Vendor determines whether each SOR identified in a supplier response is conformant by reviewing the identified SORs against the lists of conformant SORs published by the RMI. SORs classified as actively pursuing conformant status under the RMAP also are identified.

Additionally, through the Vendor, we evaluate the strength of our suppliers' 3TG due diligence and supply chain control programs, further assisting us in identifying supply chain risk. The criteria used to evaluate the program strength of our suppliers includes reviewing whether the supplier has a 3TG policy, whether it has implemented due diligence measures for conflict-free sourcing, whether it verifies due diligence information from its suppliers, and whether its verification process includes corrective action management.

3.<u>Risk Response</u> <u>Strategy</u>

Together with the Vendor, we have developed processes to assess and respond to risks in 3TG sourcing.

The Vendor or our employees made escalating contacts with unresponsive suppliers, emphasizing the importance of their response and their required cooperation for compliance with the 3TG Rule. When SORs determined to be of higher risk are reported on a CMRT by one of the suppliers surveyed, we seek to mitigate risk by requesting, through the Vendor, that the supplier take its own risk mitigation actions.

------

If we have reason to believe that a supplier is using 3TG from sources that may support conflict in the Covered Countries, we will seek to encourage it to establish an alternative source of 3TG that does not support such conflict. In addition, suppliers are guided to the Vendor's learning platform for educational materials on mitigating the risk of SORs on the supply chain.

The Vendor also directly contacts SORs that are not currently enrolled in the RMAP to encourage their participation and gather information regarding each SOR's sourcing practices.

In addition, under our Vendor Code of Conduct, if we determine or believe at any time that a supplier has failed to comply with the standards set forth in the Vendor Code of Conduct, including those with respect to 3TG, we have the right to cease the purchase of the supplier's products without liability or obligation.

We address identified risks on a case-by-case basis. This flexible approach enables us to tailor the response to the risks identified.

4.<u>Audits of Due Diligence Practices of</u> <u>SORs</u>

We do not have a direct relationship with SORs and do not perform or direct SOR audits. Instead, we rely on internationally recognized assessment programs, such as the RMAP, that facilitate and confirm independent third-party audits of SORs' supply chain due diligence practices.

5.<u>Annual Public Reporting on Supply Chain Due</u> <u>Diligence</u>

We report annually on our supply chain due diligence by filing a Form SD and a Conflict Minerals Report with the U.S. Securities and Exchange Commission. We have published our Conflict Minerals Report for the 2025 Reporting Period on our website at https:// www.cardinalhealth.com/en/about-us/environmental-social-governance/policies-and-principles.html.

**Due Diligence Results**

*Survey Results*

For the 2025 Reporting Period, we received responses from 19 of 19 surveyed suppliers. Responses were reviewed and validated as discussed earlier in this report.

*Smelters and Refiners*

Notwithstanding our due diligence, we did not conclusively determine the country of origin of, or facilities used to process, the necessary 3TG in the Products for the 2025 Reporting Period. Thus, SOR information we received from our suppliers may not be relevant to the Products and may identify SORs that are not actually in our supply chain. In addition, a majority of suppliers indicated that they received incomplete information from their suppliers and, therefore, could not provide a comprehensive list of all SORs in their supply chains.

A total of 337 known SORs were identified by suppliers. As of April 21st, 2026, 206 of these SORs, or 61%, were listed as conformant and 10 3%, were listed as active by the RMI. Additional information concerning the identified SORs is provided below.

---

| | | | | |
|:---|:---|:---|:---|:---|
| <br>**Metal** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Known SORs (Total)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Active SORs (Total)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Conformant SORs** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Conformant SORs** |
| <br>**Metal** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Known SORs (Total)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Active SORs (Total)** | **Total** | &nbsp;&nbsp;&nbsp;**% of Known SORs** |
| Gold | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;178 | 4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;91 | &nbsp;&nbsp;&nbsp;51% |
| Tantalum | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35 | 1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32 | &nbsp;&nbsp;&nbsp;91% |
| Tin | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 73 | 4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;50 | &nbsp;&nbsp;&nbsp;68% |
| Tungsten | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;51 | 1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33 | &nbsp;&nbsp;&nbsp;65% |
| Total | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 337 | 10 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;206 | &nbsp;&nbsp;&nbsp;61% |

---

We note the following in connection with the information contained in the foregoing table:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.The SORs listed in the table were identified by our suppliers as potentially being part of our 2025 supply chain. However, as noted earlier in this Conflict Minerals Report, the SORs listed above were not necessarily SORs in our 2025 supply chain.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.SOR status information in the table is as of,April 21<sup>st</sup> 2026.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.A SOR is a "known SOR" if it is listed on the Smelter Look-up tab list of the CMRT.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d."Active" means that the SOR is a known SOR and is currently engaged in the RMAP but a conformance determination has yet to be made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e."Conformant" means that a SOR is a known SOR and was listed as RMAP conformant by the RMI and successfully completed an assessment against the applicable RMAP standard or an equivalent cross-recognized assessment. Included SORs were not necessarily conformant for all or part of 2025 and may not continue to be conformant for any future period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f.SOR status reflected in the table is based solely on information made publicly available by the RMI, without independent verification by us.

The table below provides information on the SORs included in the table above that are believed to source in whole or in part from a Covered Country. We are unable to determine specifically the countries of origin of the 3TG in the Products. Accordingly, the 3TG in the Products may not have originated in a Covered Country or a particular Covered Country. The information summarized below was furnished by the Vendor based on supplier submissions. Some of the identified SORs also may have sourced in whole or in part from recycled or scrap sources.

---

| | | | |
|:---|:---|:---|:---|
| <br>**Metal** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Believed to Potentially Source From a Covered Country** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Believed to Potentially Source From a Covered Country** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Believed to Potentially Source From a Covered Country** |
| <br>**Metal** | &nbsp;&nbsp;&nbsp;**Total SORs Potentially**<br>**Sourcing from a Covered Country ("Total SORS")** | &nbsp;&nbsp;&nbsp;<br>**Total SORS as % of Known SORs** | &nbsp;&nbsp;&nbsp;&nbsp;<br>**% of Total SORs that are Conformant** |
| Gold | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 53% |
| Tantalum | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;66% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100% |
| Tin | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>73% |
| Tungsten | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;43% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 80% |
| Total | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;77 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 74% |

---

Cardinal Health's efforts to determine the mine or location of origin of the necessary 3TG in the Products with the greatest possible specificity consisted of the implementation of the Program and other due diligence measures described above in this Conflict Minerals Report.

**Additional Risk Mitigation Steps**

Since the filing of our Conflict Minerals Report last year, we have continued to utilize the Vendors' expertise in supplier surveys and supply chain traceability, which considers improvements in broader industry practice.

**Forward-Looking Statements**

This report includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties, such as whether industry organizations and initiatives remain effective as a source of external support to us in the 3TG compliance process. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as "expects," "plans," "intends," "will," "may," and similar terms and include statements reflecting future results or guidance and statements of outlook. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Forward-looking statements are not guarantees of future performance. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law. Subsequent events may affect our future determinations under the 3TG Rule.

<br>